Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.

Kishimoto TK, Qi YW, Long A, Capila I, Sasisekharan R, Guerrero L, Fier I, Roach J, Venkataraman G.

Thromb Haemost. 2009 Nov;102(5):900-6. doi: 10.1160/TH09-02-0105.

PMID:
19888526
2.

Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.

Rao SV, Melloni C, Myles-Dimauro S, Broderick S, Kosinski AS, Kleiman NS, Dzavík V, Tanguay JF, Chandna H, Gammon R, Rivera E, Alexander JH, Fier I, Roach J, Becker RC; EMINENCE Investigators.

Circulation. 2010 Apr 20;121(15):1713-21. doi: 10.1161/CIRCULATIONAHA.109.913277. Epub 2010 Apr 5.

3.

A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.

Volovyk Z, Monroe DM, Qi Y, Becker R, Hoffman M.

J Thromb Thrombolysis. 2009 Aug;28(2):132-9. doi: 10.1007/s11239-009-0360-0.

PMID:
19543696
4.

[Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].

Drozd NN, Tolstenkov AS, Bannikova GE, Miftakhova NT, Lapikova ES, Makarov VA, Varlamov VP.

Eksp Klin Farmakol. 2007 Nov-Dec;70(6):19-24. Russian.

PMID:
18318190
5.

M-118, a novel, low-molecular-weight heparin for the potential treatment of cardiovascular disorders.

Shah H, Gurm HS.

Curr Opin Investig Drugs. 2010 Sep;11(9):1059-65.

PMID:
20730701
6.

[Therapeutic indications of low molecular weight heparins].

Samama MM, Michaut-Paterno F.

Arch Mal Coeur Vaiss. 1991 Nov;84(11 Suppl):1733-43. Review. French.

PMID:
1662941
7.

Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial.

Melloni C, Fier I, Roach J, Kosinski AS, Broderick S, Sigmon K, Myles S, Becker RC, Rao SV; EMINENCE Investigators.

Am Heart J. 2009 Nov;158(5):726-33. doi: 10.1016/j.ahj.2009.08.020. Epub 2009 Sep 30.

PMID:
19853689
8.

Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.

Kodumuri V, Adigopula S, Singh P, Swaminathan P, Arora R, Khosla S.

Am J Ther. 2011 May;18(3):180-9. doi: 10.1097/MJT.0b013e3181c1218f.

PMID:
20027109
9.
10.

Factor Xa inactivation in acute coronary syndrome.

Barantke M, Bonnemeier H.

Curr Pharm Des. 2008;14(12):1186-90. Review.

PMID:
18473865
11.

Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.

Singh KP, Roe MT, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Smith SC Jr, Gibler WB, Ohman EM, Pollack CV Jr; CRUSADE Investigators.

J Thromb Thrombolysis. 2006 Jun;21(3):211-20.

PMID:
16683212
13.

Emerging anticoagulants: mechanism of action and future potential.

Klement P, Rak J.

Vnitr Lek. 2006 Mar;52 Suppl 1:119-22. Review.

PMID:
16637459
14.

Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.

Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, Collet JP, Steinhubl SR, Montalescot G.

Arch Intern Med. 2007 Dec 10;167(22):2423-30. Review.

PMID:
18071163
15.

Low molecular weight heparin: a critical analysis of clinical trials.

Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AW.

Pharmacol Rev. 1994 Mar;46(1):89-109. Review.

PMID:
8190751
16.

[Factor Xa-inhibition in interventional cardiology].

Ahrens I, Peter K, Bode C.

Hamostaseologie. 2007 Dec;27(5):328-32. German.

PMID:
18060241
17.

Monitoring therapeutic anticoagulation with low molecular weight heparins: is it useful or misleading?

Hammerstingl C.

Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):282-6. Review.

PMID:
18855641
18.

Low-molecular weight heparins in venous and arterial thrombotic disease.

Bijsterveld NR, Hettiarachchi R, Peters R, Prins MH, Levi M, Büller HR.

Thromb Haemost. 1999 Sep;82 Suppl 1:139-47.

PMID:
10695506
19.

A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.

Chen JL, Chen J, Qiao SB, Guo YL, Wu YJ, Dai J, Yuan JQ, Qin XW, Yang YJ, Gao RL.

Chin Med J (Engl). 2006 Mar 5;119(5):355-9.

PMID:
16542576

Supplemental Content

Support Center